跳至主要内容
临床试验/JPRN-jRCT1041210141
JPRN-jRCT1041210141进行中(未招募)未知

The effect of roxadustat on erythropoietin production from liver among patients on long-term maintenance hemodialysis or patients with non-dialysis dependent chronic kidney disease

Hamano Takayuki0 个研究点目标入组 40 人开始时间: 2022年2月3日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
>= 20age old 至 < 95age old(—)
性别
All

入选标准

  • Hemodialysis patients
  • age>=20 and <95
  • dialysis vintage > 15 years
  • receiving treatment with erythropoiesis stimulating agents (ESA)
  • requiring change from ESA to HIF-PH inhibitors for clinical reasons
  • those who consent to participation to the research
  • Patients with non-dialysis dependent chronic kidney disease
  • age>=20 and <95
  • receiving treatment with ESA
  • requiring change from ESA to HIF-PH inhibitors for clinical reasons
  • those who consent to participation to the research

排除标准

  • Those with malignancy
  • Those with deep venous thrombosis
  • Hematologic malignancy including myelodysplastic syndrome
  • Iron deficiency (transferrin saturation <20% or ferritin <100ng/mL)
  • Active bleeding
  • Liver dysfunction (Child Pugh class B or C)
  • Diabetic proliferative retinopathy
  • Those who were deemed to be ineligible by treating physicians

研究者

发起方
Hamano Takayuki

相似试验